Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials

People living with cancer should have access to clear and comprehensible treatment information to empower informed decision-making. With the increasing adoption of open access publishing and plain-language summaries, clinical trial findings in journals are becoming more accessible. However, this will only help patients if they are equipped with the relevant knowledge and understanding to make sense of these findings. This podcast highlights the need to support this aspect of health literacy by bringing together the perspectives of a patient, a patient advocate and a medical oncologist. It is accompanied by two visual, plain-language guides designed to help general audiences understand the key efficacy end points that are commonly used in trials of solid tumor treatments.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-12-18
DOI
https://doi.org/10.1080/14796694.2024.2433411
Citations
1
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials

Eric Kumar Singhi, Hannah FitzGibbon, Gissoo DeCotiis, Michael V. Henley
1 citations
Future Oncology
Ethics in Clinical Research
0.54
article

Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials

Eric Kumar Singhi, Hannah FitzGibbon, Gissoo DeCotiis, Michael V. Henley
article en
1 citations

Abstract

People living with cancer should have access to clear and comprehensible treatment information to empower informed decision-making. With the increasing adoption of open access publishing and plain-language summaries, clinical trial findings in journals are becoming more accessible. However, this will only help patients if they are equipped with the relevant knowledge and understanding to make sense of these findings. This podcast highlights the need to support this aspect of health literacy by bringing together the perspectives of a patient, a patient advocate and a medical oncologist. It is accompanied by two visual, plain-language guides designed to help general audiences understand the key efficacy end points that are commonly used in trials of solid tumor treatments.

Future OncologyVol. 21(1)
The University of Texas MD Anderson Cancer Center (US), Daiichi Sankyo (Germany) (DE), China Institute Of Communications (CN), Daiichi-Sankyo (South Korea) (KR), Daiichi Sankyo (United States) (US), National Patient Safety Foundation (US)
Daiichi Sankyo Europe
Openalex Percentile: Top 26%
Ethics in Clinical Research
0.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials — Eric Kumar Singhi, Hannah FitzGibbon, et al. · Future Oncology (2024) | TGRS Research Map | TGRS